Form 4: Dyne Therapeutics CSO Sells Shares to Cover Tax Obligations

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold 1,094 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• On March 5, 2025, Oxana Beskrovnaya, the Chief Scientific Officer of Dyne Therapeutics, sold 1,094 shares of Dyne Therapeutics common stock.
• The sale was executed at a weighted average price of $11.83 per share, with individual transactions ranging from $11.73 to $11.94.
• The sale was to cover tax withholding obligations related to the vesting of restricted stock units granted on December 4, 2024.
• Following the transaction, Beskrovnaya beneficially owns 197,993 shares of Dyne Therapeutics, including 157,622 unvested RSUs.
• The sale was conducted under a pre-arranged plan (Rule 10b5-1) to satisfy tax obligations.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (sale of shares to cover tax obligations) by a company executive. It doesn't indicate any fundamental issues with the company, but it's also not overwhelmingly positive. Therefore, a neutral sentiment score is appropriate.

Industry Context

Sales of shares by company executives are a normal part of corporate governance, especially when related to covering tax obligations from vesting equity. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid any appearance of insider trading.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time.
• Upon vesting, these RSUs are subject to income tax, and executives often sell a portion of their shares to cover these tax liabilities.
• The use of Rule 10b5-1 trading plans is a standard practice among public company executives to ensure compliance with insider trading regulations.
• Comparable companies in the biotechnology sector, such as Sarepta Therapeutics and BioMarin Pharmaceutical, also see similar transactions by their executives.

Stakeholder Impact

• The sale of shares by the CSO may have a minor, temporary impact on the stock price, but it is unlikely to be significant given the relatively small number of shares involved.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates